No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
DK Delek US
- 21.630
- +0.010+0.05%
Close Jul 19 16:00 ET
- 21.670
- +0.040+0.18%
Post 16:07 ET
1.39BMarket Cap-18646P/E (TTM)
21.800High21.155Low887.76KVolume21.680Open21.620Pre Close19.12MTurnover1.42%Turnover Ratio72.10P/E (Static)64.13MShares33.29952wk High1.62P/B1.35BFloat Cap21.15552wk Low0.95Dividend TTM62.53MShs Float52.411Historical High4.39%Div YieldTTM2.98%Amplitude2.056Historical Low21.537Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Wolfe Research Reinstates Underperform on Delek US Hldgs
Wolfe Research Downgrades Delek US(DK.US) to Sell Rating
Wolfe Research analyst Sam Margolin downgrades $Delek US(DK.US)$ to a sell rating.According to TipRanks data, the analyst has a success rate of 67.4% and a total average return of 12.7% over the
Piper Sandler Maintains Delek US(DK.US) With Hold Rating, Maintains Target Price $25
Piper Sandler analyst Ryan Todd maintains $Delek US(DK.US)$ with a hold rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 56.1% and a total
Express News | Wells Fargo Maintains Underweight on Delek US Hldgs, Lowers Price Target to $20
Wells Fargo Maintains Delek US(DK.US) With Sell Rating, Cuts Target Price to $20
Wells Fargo analyst Roger Read maintains $Delek US(DK.US)$ with a sell rating, and adjusts the target price from $25 to $20.According to TipRanks data, the analyst has a success rate of 63.2% and a
Express News | Delek US Holdings, Inc. : Wells Fargo Cuts Target Price to $20 From $25
Comments
Delek US Holdings' low P/S ratio is due to predicted revenue decline. Investors see no significant potential for revenue growth to justify a higher P/S ratio. Without major changes, a significant stock price increase is unlikely. The company's weak outlook is pressuring the shares downwards.
Benign Growth For Delek US Holdings, Inc. (NYSE:DK) Underpins Its Share PriceThe board of Delek US Holdings expresses positive sentiment towards the appointment of Ms. Benson, highlighting her experience in risk management, capital markets, and green energies as instrumental for the company's strategic initiatives.
Delek's lower Return on Equity (ROE) coupled with high debt levels make it less attractive for investment. Investors should also consider profit growth rates and market expectations before investing in Delek or similar companies.
Gainers:
• $La-Z-Boy(LZB.US$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer(PFE.US$)
• $Ikena Oncology(IKNA.US$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
• $La-Z-Boy(LZB.US$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer(PFE.US$)
• $Ikena Oncology(IKNA.US$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
8
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg